Jun 24, 2020 / 08:00PM GMT
Operator
Good afternoon, and welcome to the Insmed Post-ATS Investor Call to review brensocatib WILLOW data and a program review. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Sara Bonstein. Please go ahead.
Sara M. Bonstein - Insmed Incorporated - CFO
Thank you. Good afternoon, and welcome to today's conference call to discuss new data from our Phase II WILLOW study of brensocatib in non-cystic fibrosis bronchiectasis, presented earlier today at the American Thoracic Society Virtual Meeting.
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements. Please refer to our filings with the SEC, which are available through the SEC's website at www.sec.gov or from our
Insmed Inc to Discuss Data Presented at American Thoracic Society - Conference Call Transcript
Jun 25, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers